Becton Dickinson and (BDX)
198.71
-1.69 (-0.84%)
At close: Apr 17, 2025, 3:59 PM
201.71
1.51%
After-hours: Apr 17, 2025, 08:00 PM EDT
Becton Dickinson and Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Revenue | 4.04B | 2.1B | 1.3B | 1.29B | n/a | 1.22B | 1.19B | 1.13B | n/a | 1.14B | 1.49B | 1.11B | n/a | 1.43B | 1.01B | 1.98B | n/a | 782M | 990M | 1.01B | n/a | 981M | 963M | 970M | 1.13B | 954M | 1.1B | 1.04B | 1.05B | 997M | 982M | 958M | 997M | 963M | 936M | 933M | 2.08B | 921M | 945M | 979M | 301M | 277M | 302M | 279M | 300.69M | 257.06M | 279.36M | 264.89M | 155.31M | 268.2M | 339.61M | 316.5M | 1B | 337.89M |
| Interventional Revenue Growth | +92.24% | +61.04% | +1.24% | n/a | -100.00% | +2.70% | +5.05% | n/a | -100.00% | -23.10% | +33.18% | n/a | -100.00% | +41.74% | -48.91% | n/a | -100.00% | -21.01% | -2.17% | n/a | -100.00% | +1.87% | -0.72% | -14.24% | +18.55% | -13.11% | +5.07% | -0.57% | +5.42% | +1.53% | +2.51% | -3.91% | +3.53% | +2.88% | +0.32% | -55.21% | +126.17% | -2.54% | -3.47% | +225.25% | +8.66% | -8.28% | +8.24% | -7.21% | +16.97% | -7.99% | +5.46% | +70.55% | -42.09% | -21.03% | +7.30% | -68.45% | +196.92% | n/a |
| Life Sciences Revenue | 299M | 2.3B | 1.11B | 1.05B | n/a | 1.23B | 1.27B | 1.3B | n/a | 1.31B | 1.04B | 1.48B | n/a | 1.01B | 1.59B | 1.01B | n/a | 951M | 1.11B | 1.12B | n/a | 1.06B | 1.05B | 1.06B | 1.11B | 1.08B | 2.17B | 2.04B | 2.12B | 2.04B | 1.99B | 1.96B | 2.23B | 2.23B | 2.13B | 2.05B | 977M | 2.2B | 1.11B | 1.07B | 1.9B | 1.88B | 1.77B | 1.74B | 1.15B | 1.8B | 2.05B | 1.95B | 2.01B | 2.02B | 1.96B | 1.88B | 5.71B | 1.98B |
| Life Sciences Revenue Growth | -87.00% | +107.77% | +5.23% | n/a | -100.00% | -3.84% | -2.07% | n/a | -100.00% | +26.11% | -30.01% | n/a | -100.00% | -36.51% | +57.34% | n/a | -100.00% | -14.56% | -0.89% | n/a | -100.00% | +0.57% | -0.38% | -4.69% | +2.69% | -50.32% | +6.73% | -3.83% | +3.83% | +2.57% | +1.17% | -12.09% | -0.04% | +4.88% | +3.75% | +110.24% | -55.57% | +98.82% | +3.17% | -43.61% | +1.12% | +6.27% | +1.90% | +50.43% | -35.73% | -12.41% | +4.99% | -2.94% | -0.47% | +3.23% | +4.41% | -67.18% | +188.95% | n/a |
| Medical Revenue | 5.82B | n/a | 489M | 454M | n/a | 2.43B | 2.36B | 2.15B | n/a | 2.19B | 450M | 2.4B | n/a | 436M | 2.31B | 426M | n/a | 2.12B | 2.15B | 2.09B | n/a | 2.31B | 2.18B | 2.13B | 2.16B | 2.25B | 952M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Medical Revenue Growth | n/a | n/a | +7.71% | n/a | n/a | +3.14% | +9.56% | n/a | n/a | +386.89% | -81.23% | n/a | n/a | -81.13% | +442.49% | n/a | n/a | -1.35% | +2.92% | n/a | n/a | +6.01% | +2.11% | -1.29% | -3.70% | +135.92% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | Sep 30, 2015 | Sep 30, 2014 | Sep 30, 2013 | Sep 30, 2012 | Sep 30, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asia Revenue | 2.91B | 2.91B | 3.05B | 3.27B | 2.57B | 2.73B | 2.46B | 1.74B | 1.69B | 1.54B | 1.12B | 1.01B | 883.29M | 684.32M |
| Asia Revenue Growth | -0.24% | -4.40% | -6.88% | +27.41% | -5.80% | +10.81% | +41.06% | +3.07% | +9.51% | +37.82% | +11.43% | +13.89% | +29.08% | n/a |
| Europe Revenue | 4.4B | 4.24B | 4.04B | 4.75B | 3.48B | 3.36B | 3.3B | 2.59B | 3.05B | 2.43B | 2.73B | 2.51B | 2.38B | 2.39B |
| Europe Revenue Growth | +3.72% | +4.97% | -14.90% | +36.52% | +3.60% | +1.85% | +27.43% | -15.12% | +25.27% | -10.94% | +8.80% | +5.60% | -0.34% | n/a |
| Others Country Revenue | 1.21B | 1.1B | 1.06B | 1.25B | 1.35B | 1.48B | 1.46B | 1.26B | 849M | 1.23B | 1.18B | 1.18B | 1.16B | 1.01B |
| Others Country Revenue Growth | +9.53% | +4.16% | -15.70% | -7.24% | -8.33% | +1.30% | +15.91% | +48.06% | -31.20% | +5.02% | -0.68% | +2.10% | +14.21% | n/a |
| United States Revenue | 11.66B | 11.11B | 10.72B | 10.97B | 9.72B | 9.73B | 8.77B | 6.5B | 6.89B | 5.07B | 3.42B | 3.35B | 3.29B | 3.29B |
| United States Revenue Growth | +4.95% | +3.65% | -2.25% | +12.90% | -0.14% | +10.97% | +34.81% | -5.64% | +35.98% | +48.35% | +1.91% | +1.99% | +0.03% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.32B | 1.26B | 1.2B | 1.19B | 1.21B | 1.14B | 1.19B | 1.21B | 1.19B | 1.18B | 1.15B | 1.23B | 1.19B | 1.33B | 1.24B | 1.15B | 1.15B | 1.2B | 980M | 1.02B | 1.12B | 1.09B | 1.08B | 1.09B | 1.07B | 1.1B | 1.08B | 1.06B | 774M | 774M | 719M | 724M | 709M | 796M | 728M | 732M | 748M | 756M | 764M | 511M |
| Selling, General, and Administrative Revenue Growth | +4.94% | +5.02% | +0.25% | -1.65% | +6.68% | -4.45% | -1.24% | +1.52% | +0.42% | +2.87% | -6.74% | +3.97% | -11.04% | +7.68% | +7.75% | -0.09% | -4.25% | +22.45% | -4.39% | -8.56% | +2.47% | +1.67% | -1.19% | +1.49% | -2.72% | +2.04% | +2.27% | +36.56% | 0.00% | +7.65% | -0.69% | +2.12% | -10.93% | +9.34% | -0.55% | -2.14% | -1.06% | -1.05% | +49.51% | n/a |
| Research and Development Revenue | 343M | 302M | 299M | 299M | 290M | 281M | 306M | 337M | 313M | 300M | 315M | 343M | 314M | 387M | 344M | 317M | 291M | 299M | 262M | 264M | 270M | 270M | 282M | 252M | 258M | 278M | 277M | 260M | 192M | 221M | 186M | 187M | 182M | 253M | 207M | 182M | 187M | 196M | 178M | 129M |
| Research and Development Revenue Growth | +13.58% | +1.00% | 0.00% | +3.10% | +3.20% | -8.17% | -9.20% | +7.67% | +4.33% | -4.76% | -8.16% | +9.24% | -18.86% | +12.50% | +8.52% | +8.93% | -2.68% | +14.12% | -0.76% | -2.22% | 0.00% | -4.26% | +11.90% | -2.33% | -7.19% | +0.36% | +6.54% | +35.42% | -13.12% | +18.82% | -0.53% | +2.75% | -28.06% | +22.22% | +13.74% | -2.67% | -4.59% | +10.11% | +37.98% | n/a |